NCT07096310View on ClinicalTrials.gov

Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 15, 2026

Study Completion Date

March 1, 2026

Conditions
Sepsis
Interventions
DRUG

Meropenem I.V. 2g as a 3 hour infusion every 8 hours

Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day

DRUG

Tazocin (pipercillin/tazobactam)

Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day

Trial Locations (1)

002

Ain Shams University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT07096310 - Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients | Biotech Hunter | Biotech Hunter